| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendiceal Neoplasms | 6 | 2024 | 234 | 1.050 |
Why?
|
| Colitis | 4 | 2022 | 340 | 0.640 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2023 | 1724 | 0.450 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 3578 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5061 | 0.340 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 986 | 0.300 |
Why?
|
| Adenocarcinoma | 5 | 2024 | 7789 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 493 | 0.250 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 493 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 4975 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 821 | 0.220 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 411 | 0.220 |
Why?
|
| Pancreatitis, Chronic | 1 | 2023 | 116 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2023 | 268 | 0.220 |
Why?
|
| Biopsy | 5 | 2020 | 3443 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2022 | 1038 | 0.200 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Diarrhea | 2 | 2021 | 686 | 0.180 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2023 | 436 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2021 | 176 | 0.170 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 102 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.170 |
Why?
|
| Hyperthermia, Induced | 1 | 2023 | 510 | 0.160 |
Why?
|
| Genomics | 3 | 2021 | 2738 | 0.160 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 342 | 0.160 |
Why?
|
| Middle Aged | 21 | 2024 | 86204 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 565 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 10331 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 108 | 0.150 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2018 | 690 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2021 | 1385 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 479 | 0.140 |
Why?
|
| Stem Cell Factor | 1 | 2016 | 87 | 0.140 |
Why?
|
| Aged | 17 | 2024 | 70117 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 4367 | 0.140 |
Why?
|
| Smad2 Protein | 1 | 2016 | 89 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2020 | 911 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2016 | 113 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1350 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1048 | 0.130 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2015 | 38 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 292 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.120 |
Why?
|
| Microsatellite Instability | 3 | 2023 | 400 | 0.120 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2014 | 38 | 0.120 |
Why?
|
| Male | 21 | 2023 | 123000 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 7548 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2019 | 544 | 0.120 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 103 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 29902 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 760 | 0.120 |
Why?
|
| Calcinosis | 1 | 2017 | 423 | 0.120 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 469 | 0.120 |
Why?
|
| Cholestasis | 1 | 2016 | 203 | 0.120 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 4557 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 1249 | 0.110 |
Why?
|
| Humans | 30 | 2024 | 261506 | 0.110 |
Why?
|
| Prognosis | 7 | 2023 | 21713 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 480 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 519 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 1248 | 0.110 |
Why?
|
| Female | 20 | 2023 | 141928 | 0.110 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2012 | 109 | 0.100 |
Why?
|
| Adult | 13 | 2021 | 77950 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 15862 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 5437 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2014 | 584 | 0.100 |
Why?
|
| Retrospective Studies | 10 | 2024 | 37905 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 221 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 231 | 0.090 |
Why?
|
| Survival Rate | 5 | 2023 | 12221 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1763 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2023 | 475 | 0.090 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 980 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2054 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1870 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2014 | 1555 | 0.080 |
Why?
|
| Lymphoma | 1 | 2016 | 1467 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 7551 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5178 | 0.070 |
Why?
|
| Colonoscopy | 2 | 2021 | 518 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10035 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2023 | 652 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 3168 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.070 |
Why?
|
| Mutation | 4 | 2020 | 15179 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5159 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1742 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 2027 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 222 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2023 | 105 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 144 | 0.060 |
Why?
|
| Risk Factors | 4 | 2021 | 17523 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 226 | 0.050 |
Why?
|
| Leucovorin | 1 | 2023 | 332 | 0.050 |
Why?
|
| Liver | 3 | 2017 | 2961 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 2218 | 0.050 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Observer Variation | 1 | 2023 | 671 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.050 |
Why?
|
| Mucins | 1 | 2023 | 285 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 460 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 76 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 132 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 43 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 269 | 0.050 |
Why?
|
| Chromogranins | 1 | 2020 | 84 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2021 | 216 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3552 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 12873 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2021 | 155 | 0.050 |
Why?
|
| Pancreas | 1 | 2023 | 718 | 0.040 |
Why?
|
| Thioguanine | 1 | 2019 | 68 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 334 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 343 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 184 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 5112 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1944 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 275 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2019 | 301 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 495 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1382 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 14289 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 698 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 13658 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2021 | 32848 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 28 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 1064 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 375 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 6100 | 0.040 |
Why?
|
| Genes, ras | 1 | 2020 | 667 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 629 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 8873 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1033 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 670 | 0.030 |
Why?
|
| Gastritis | 1 | 2019 | 373 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 613 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 34495 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 521 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 1081 | 0.030 |
Why?
|
| Time Factors | 2 | 2020 | 12926 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 221 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 16 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 278 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1519 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 4821 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 14551 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 448 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 1823 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 101 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9244 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 3570 | 0.030 |
Why?
|
| Cytarabine | 1 | 2019 | 1973 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2522 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 483 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1351 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 2083 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 14889 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 104 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 31252 | 0.030 |
Why?
|
| Animals | 3 | 2022 | 59536 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 8865 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 157 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 1408 | 0.030 |
Why?
|
| Chromatin | 1 | 2017 | 942 | 0.030 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 155 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 598 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 973 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1217 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2216 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 1282 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 576 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 483 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3101 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 1121 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1509 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5673 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 6311 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4532 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4744 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 688 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3981 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 3154 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3639 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 4844 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 701 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 2173 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 6150 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2017 | 2669 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2483 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3230 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 3343 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6682 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 7226 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 5270 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 11965 | 0.010 |
Why?
|